Send us a text A lab surprise turned frontline hope: we sit down with Dr Liz Dallimore, CEO of Argenica Therapeutics, to unpack a peptide drug designed to protect the brain during the chaotic minutes after stroke and other injuries. Built from a chain of arginines, the therapy targets the glutamate‑driven calcium surge that kills neurons, aiming to stabilise tissue while clot dissolvers or thrombectomy restore blood flow. We trace Argenica’s journey from Perth lab benches to a multi‑centre P...
All content for ASX BRIEFS is the property of Andrew Musgrave and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Send us a text A lab surprise turned frontline hope: we sit down with Dr Liz Dallimore, CEO of Argenica Therapeutics, to unpack a peptide drug designed to protect the brain during the chaotic minutes after stroke and other injuries. Built from a chain of arginines, the therapy targets the glutamate‑driven calcium surge that kills neurons, aiming to stabilise tissue while clot dissolvers or thrombectomy restore blood flow. We trace Argenica’s journey from Perth lab benches to a multi‑centre P...
Send us a text Ever wondered how a small Australian explorer becomes a key player in America's critical minerals strategy? Jindalee Lithium's story might just be the blueprint. The race for battery metal security is reshaping global mining, and Jindalee has positioned itself at the center of America's lithium ambitions. In this compelling conversation with CEO Ian Rodger, we dive deep into the McDermitt Project – one of the largest lithium resources in the United States, strategically locate...
ASX BRIEFS
Send us a text A lab surprise turned frontline hope: we sit down with Dr Liz Dallimore, CEO of Argenica Therapeutics, to unpack a peptide drug designed to protect the brain during the chaotic minutes after stroke and other injuries. Built from a chain of arginines, the therapy targets the glutamate‑driven calcium surge that kills neurons, aiming to stabilise tissue while clot dissolvers or thrombectomy restore blood flow. We trace Argenica’s journey from Perth lab benches to a multi‑centre P...
